Autoantibodies Against Beta(1)-Adrenergic Receptor: Response To Induction Therapy With Bortezomib-Containing Regimens For Multiple Myeloma Patient

This study aims to investigate the predictive value of pre-chemotherapy beta 1R-AABs by evaluating the response of newly diagnosed symptomatic multiple myeloma (MM) patients to their treatment with a bortezomib-containing regimen. Forty-five de novo MM patients and 50 normal controls (NCs) were prospectively enrolled in this study. Serum titers of beta 1R-AABs were detected by ELISA. These 45 MM patients were divided into two groups (positive and negative groups) according to their beta 1R-AABs. Follow-up examinations were performed on these patients during chemotherapy induction. The final analysis covered all 45 MM patients, including 19 patients who were positive for MM and 26 patients who were negative for MM. Multivariate analysis revealed that pre-chemotherapy beta 1R-AABs are possibly independent predictors for less than very good partial response (VGPR) after the bortezomib-containing regimen treatment (odds ratio: 5.967, 95% confidence interval: 1.513-23.531; p=.011). This study demonstrates for the first time that the presence of beta 1R-AABs is associated with MM. Pre-chemotherapy beta 1R-AABs are independent predictors for less than VGPR in de novo MM patients after the bortezomib-containing regimen was administrated. Bortezomib might not significantly give rise to cardiac impairment in MM patients.